Compared with the normal control group, the TYR content in the model group was significantly reduced (P < 0.05); however, the content of TYR in the CWT groups showed a dose-related increase, especially in the CWT-M and CWT-H groups (P < 0.05) (Figure 2(a)), and this was higher than in the BC-treated positive control. This evidence concerns the gene TYR and breast cancer.